Document is current
Any future updates will be listed below
-
Authors
Zafardoust, Simin
Didar, Hamidreza
Ganagard, Maryam Ghasemi
Tavakoli, Maryam
Arefi, Soheila
Arjmandinaloo, Shaghayegh
Fathi-Kazerooni, Mina https://orcid.org/0000-0003-0581-2326
- License Information
-
More Information
Article History
Received: 23 December 2024
Accepted: 12 March 2025
First Online: 12 April 2025
Declarations
:
: The study was started after providing complete information to patients and obtaining signed written consent. This clinical study was conducted with the permission of the Ethics Committee for Biomedical Research of the Academic Center for Education, Culture, and Research (ACECR, Tehran, Iran) (IR.ACECR.REC.1397.002, 2018–05-06 and IR.ACECR.REC.1399.002, 2020–05-31) under the title "Evaluation of the safety and feasibility of intra-ovarian injection of menstrual blood stem cells in women with poor ovarian responders (POR)”. All procedures observed were under the Declaration of Helsinki, Good Clinical Practice (GCP), and GMP guidelines. Furthermore, this study was registered with the Iranian Clinical Trials Registry (IRCT20180619040147N2) and ClinicalTrials.gov (NCT05703308). The cell manufacturing was performed by STERCO (Tehran, Iran) in a GMP clean room authorized by Iran Food and Drug Administration authorities.
: Not relevant.
: The authors declare that they have no competing interests.
